Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If you look at it over a month and it only up 4% and down 28% over 6 months also when I wrote that it was trading at 58.50
Err, is it not up today?
Agree I would like and expect to see a bigger rise.
How come we have 2 big investment companies saying they own shares and the sp hasn't moved
Global investment management group based in Australia. .J O Hambro Capital Management are a London based subsidiary.
Interest growing?
Thanks Balanced, looks like they didn't complete the form correctly this time, it appears to show no holding to 9%.
Still, it's good to have an institutional buyer.
ALB
A quick look and they seem to have just increased their holding slightly so likely bought from the impatient sellers. Some big purchases have been showing in the daily trades in the last few weeks.
https://www.lse.co.uk/rns/DNL/holdings-in-company-ygjhwmhkf19pmh0.html
That's very peculiar............how have they done that below the radar? They must have taken the shares off another inti surely?
Have acquired 9% of shares without anyone noticing. Despite the poor share price performance, institutions still seem to be taking positions here.
ALB
https://www.edisongroup.com/publication/efmody-launched-in-the-eu-and-uk/29979
Encouraging recovery back towards 60p ...
Meant to finish that and say it was on in the background while I was doing something else so will listen more carefully later
These results were already flagged earlier in the year. Listened to the presentation this morning - had it on in the background.
I'm more positive about the company after listening to the presentation and feel they will succeed in Europe with the roll out for Efmody and also therefore for rest of the world.
Just atm dnl is on a slow boat to China and burns money faster than my ex ! Glad I see what dnl become no regrets here atb those holding
Zero SP appreciation over the year, big salaries and bonuses & LTIP paid but little skin in the game from BOD and more funding required as per RNS: Diurnal expects its cash resources to take its core commercial European cortisol deficiency franchise through to profitability based upon current plans and assumptions, including expectations regarding the timing of product approvals and sales projections. The Group intends to 'ringfence' this franchise and to seek incremental funding and/or partnering arrangements for discrete, future development opportunities. These plans assume that Diurnal enters into a licensing agreement for the commercialisation of Efmody® in the US, and does not include the potential for investment in DITEST™ Phase 3 clinical development and/or Efmody® US studies in adrenal insufficiency, which could require additional financing being available to the Group if the Group was unable to self-finance these activities through its operating cashflows, through additional equity investment, non-dilutive financing and/or partnering arrangements.
The BOD needs to start delivering - they have not even put the full accounts up on their site for scruntiny - taking PI for a cash ride!
Zero SP appreciation over the year, big salaries and bonuses & LTIP paid but little skin in the game from BOD and more funding required as per RNS: Diurnal expects its cash resources to take its core commercial European cortisol deficiency franchise through to profitability based upon current plans and assumptions, including expectations regarding the timing of product approvals and sales projections. The Group intends to 'ringfence' this franchise and to seek incremental funding and/or partnering arrangements for discrete, future development opportunities. These plans assume that Diurnal enters into a licensing agreement for the commercialisation of Efmody® in the US, and does not include the potential for investment in DITEST™ Phase 3 clinical development and/or Efmody® US studies in adrenal insufficiency, which could require additional financing being available to the Group if the Group was unable to self-finance these activities through its operating cashflows, through additional equity investment, non-dilutive financing and/or partnering arrangements.
The BOD needs to start delivering - they have not even put the full accounts up on their site for scruntiny - taking PI for a cash ride!
RNS today on Germany and Austria gives more substance to company progress but without some idea of revenue generation it is not something to get too excited about. There might have been an uptick in SP but there are other opportunities with more going on.
Full year results will be important and with a better idea of when the company will be profitable there may be more interest. DNL are well funded for the present. Mcap reflects some of the potential but there is a long way to go to get sales, revenue and profit high enough to justify a big SP rise. One to slowly build a position perhaps.
25-Aug-21 18:18:14 59.90 1,809,999 Unknown*
25-Aug-21 17:30:11 60.20 1,809,999 Buy*
It looks like a matched buy / sell with the difference being commission to the market maker..Possibly a move from one major holder to another...
Coffee always a good idea.
I note two v large trade reports at exactly the same times on the same day over at RENE…
Ignore me that was from yesterday - need coffee
Is that another huge buy as well?
V interesting £1m buy at 17:30:11 today at 60.2p.
It pretty much tells you what the “fiasco” is in the first few lines. They failed to list the side effects in an advertisement. Typical salesman though you never tell someone the bad things about your product. Unfortunately with drugs you have to.
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-reports-second-quarter-financial-results
Similar story to DNL results, Covid effects uptake due to need for one to one contact, but positive about it as they move away from the toughest effects of the pandemic.
Looks like they will need to provide better information describing the risks associated with the treatment and respond to the FDA, so should not significantly impact on Alkindi sales growth. Eton may be able to successfully show they have not violated FDA regs. Let's see.
"The FDA urges Eton (ETON) to stop the violations and requires it to provide a written response addressing the concerns within 15 working days of the receipt of the letter."